US Treasury’s Final Earnings Stripping Guidance Keeps Pressure On Inversions
Executive Summary
The US Treasury released final guidance to eliminate one of the economic motivations behind inversion deals, the threat of which in April derailed the Pfizer/Allergan mega merger. It doesn’t, however, affect other practices as feared.
You may also be interested in...
Biden Infrastructure Plan Offers Biopharma R&D Carrot, Tax Stick
Tens of billions would go to fund R&D, including Phase I and Phase II development of vaccines. But the plan would also crack down on inversions and offshoring.
Death And Tax Inversion: Policy Fight Won't Go Away, Now Spawning Lawsuits
US Chamber of Commerce wants court to eliminate IRS rule that blocked Pfizer's acquisition of Allergan; AbbVie hit with second suit over its 2014 proposed acquisition of Shire.
The Fall Of Pfizergan: The Beginning, The End And Everything In Between
The $160bn mega-merger that never came to be was exciting to watch unfold from beginning to the stunning end, when it was derailed by the US government. “The Pink Sheet” followed every twist and turn along the way.